medRxiv · Nov 17, 2026
Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial
By Sehrawat A, Shi R, Farinas MF et al.
Lithium (Li) demonstrates neuroprotective effects relevant to Alzheimer disease (AD). However, its molecular mechanisms remain insufficiently characterized. This study analyzed plasma proteomic profiles from the Li as a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) randomized clinical trial to identify markers associated with amyloid beta pathology, disease progression, and response to Li treatment. In the LATTICE trial, 80 older adults with mild cognitive impairment (MCI) were randomly assigned to receive either low-dose Li carbonate or placebo for two years. Longitudinal plasma samples were analyzed using the NULISAseq CNS Disease Panel 120 proteomic panel. Baseline protein levels were compared according to randomized treatment assignment, amyloid beta PET status, and MCI subtype. Analyses included longitudinal changes in protein levels associated with treatment and time, associations between baseline protein levels and subsequent cognitive, functional, and neuroimaging trajectories, and the influence of baseline protein levels on Li treatment effects. Among the 80 participants, 62 had amnestic MCI and 21 were positive on amyloid beta PET. Baseline proteomic differences were more strongly associated with amyloid beta PET status than with randomized treatment assignment. Plasma p-tau217 concentrations were elevated in individuals who were positive on amyloid beta PET and remained significant after false discovery rate correction. Over time, CALB2 and TREM2 exhibited nominal treatment-by-time interactions in the full cohort, while in the amnestic MCI subgroup, CALB2, TREM2, and amyloid beta 40 demonstrated nominal effects. None persisted after multiple-testing correction. GDF15 showed the most consistent associations with CDR Sum of Boxes trajectories and treatment-effect modification that remained significant after false discovery rate correction in the amnestic MCI subgroup, whereas p-tau217 was most consistently associated with hippocampal volume trajectories. Other protein-outcome associations were exploratory. Plasma proteomics identified distinct molecular patterns associated with amyloid beta pathology and the MCI phenotype, along with exploratory evidence of Li-associated protein changes. Plasma GDF15 and p-tau217 emerged as potential markers of clinical progression and treatment-response heterogeneity, warranting validation in larger, adequately powered trials.
doi.org/10.64898/2026.11.14.26368038Open accessInterventions